Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy for lung cancer under Real-World watch

NCT ID NCT07563205

Knowledge-focused Sponsor: GFPC Investigation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study follows 100 adults with metastatic non-small cell lung cancer who have certain EGFR gene mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers will collect medical data to see how long the treatment keeps the cancer from progressing. No extra tests are needed—just routine care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
amivantamab plus platinum-based chemotherapy
What this could lead to
If successful, this study could show that combining amivantamab with chemotherapy helps control metastatic lung cancer longer in people with specific EGFR mutations.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also small (100 people) and only follows participants for about 1.5 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Principal investigator of GFPC or partner centers will identify consecutive patients eligible for the inclusion from the patient population of their center (public hospital or private clinics).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient over 18 years old * Cohort A: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion treated with amivantamab-platimum based chemotherapy via an early access program in first line setting. * Cohort B: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 19 or 21 treated with amivantamab-platimum based chemotherapy post osimertinib (with or without chemotherapy) via an early access program. * Patient covered by the French National Health Insurance system or by an approved third-party payer * Patient who does not object to the collection of their personal data for research purposes (an information sheet will be provided to all living participants; for deceased participants, documented non-opposition in the medical record is not required) Exclusion Criteria: * Patient placed under legal guardianship or subject to a protective legal measure * Patient who explicitly refuses the collection or use of their personal data for research purposes * Patient not enrolled, managed, or followed at the investigating site by a qualified site investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR EGFR exon 19 deletion mutation EGFR exon 20 insertion mutation EGFR exon 21 mutation Non small cell lung cancer Non-small cell lung cancer (NSCLC) Non-small cell lung cancer metastatic Non-small cell lung carcinoma NSCLC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP Hôpital Avicennes

    RECRUITING

    Bobigny, 93000, France

  • CH de la Région d'Annecy - Service de Pneumologie

    RECRUITING

    Pringy, 74374, France

  • CH du Pays d Aix - Service des Maladies Respiratoires

    RECRUITING

    Aix-en-Provence, 13616, France

  • CHRU de Nancy

    ACTIVE_NOT_RECRUITING

    Nancy, 54000, France

  • CHU La Réunion Site Sud

    RECRUITING

    Saint-Pierre, 97410, France

  • Centre Antoine Lacassagne

    ACTIVE_NOT_RECRUITING

    Nice, 06149, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69373, France

  • Hôpital A. Mignot

    RECRUITING

    Le Chesnay, 78157, France

  • Hôpital Louis Pradel

    ACTIVE_NOT_RECRUITING

    Bron, 69500, France

  • Hôpital Nord

    RECRUITING

    Marseille, 13915, France

  • Institut Curie

    ACTIVE_NOT_RECRUITING

    Paris, 75005, France

  • Pneumologie CHU St Etienne

    RECRUITING

    Saint-Etienne, 42270, France

  • Pneumologie Centre François Baclesse

    ACTIVE_NOT_RECRUITING

    Caen, 14000, France

  • Pneumologie Centre Hospitalier Intercommunal de Créteil

    RECRUITING

    Créteil, 94010, France

  • Pneumologie Hôpital Calmette

    RECRUITING

    Lille, 59000, France

  • Pneumologie Hôpital privé Jean Mermoz

    RECRUITING

    Lyon, 69085, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.